BioCryst Pharmaceuticals (NASDAQ:BCRX) Now Covered by Wedbush

Wedbush started coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage issued an outperform rating and a $15.00 target price on the biotechnology company’s stock.

Several other research firms have also weighed in on BCRX. Needham & Company LLC raised their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. JMP Securities restated a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Trading Down 0.1 %

BioCryst Pharmaceuticals stock opened at $8.28 on Tuesday. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -13.57 and a beta of 1.75. The company’s 50-day moving average price is $8.05 and its two-hundred day moving average price is $7.85. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. During the same quarter last year, the firm posted $0.28 earnings per share. The company’s revenue for the quarter was up 40.8% compared to the same quarter last year. Research analysts expect that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BCRX. Vanguard Group Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock worth $164,616,000 after purchasing an additional 1,583,826 shares during the period. Eversept Partners LP boosted its holdings in shares of BioCryst Pharmaceuticals by 269.9% during the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company’s stock worth $14,892,000 after purchasing an additional 1,444,907 shares during the period. Hillsdale Investment Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 65,213.3% during the fourth quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company’s stock worth $4,077,000 after purchasing an additional 541,270 shares during the period. Balyasny Asset Management L.P. acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $3,983,000. Finally, Norges Bank acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $3,947,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.